Nicotine alleviates MPTP-induced nigrostriatal damage through modulation of JNK and ERK signaling pathways in the mice model of Parkinson’s disease

Introduction: Nicotine (Nic) has previously been proven to reduce neurodegeneration in the models of Parkinson’s disease (PD). The present study is intended to investigate the detailed mechanisms related to the potential neuroprotective effects of Nic in vivo. Methods: We established a PD model using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced C57BL6 mice (25 mg/kg/d, 5 d, i.p.) to investigate the neuropharmacological modulation of Nic pretreatment (2.5 mg/kg/d, 5 d, i.p., 30 min before MPTP injection) from the perspectives of neurobehavioral assessment, the pathological alterations, microglial cell inflammation and MAPK signaling pathways in specific brain regions. Results: The open field test, elevated plus maze, rotarod and traction test suggested that Nic pretreatment could significantly improve MPTP-induced motor impairment and had an anxiolytic effect. Nic was found to improve neuroapoptosis, enhance tyrosine hydroxylase activity, and reduce the accumulation of the phosphorylated α-synuclein in the substantia nigra and striatal regions of PD mice by TUNEL and immunohistochemical assays. Immuno-fluorescent method for labeling Iba1 and CD68 indicated that Nic remarkably alleviates the activation of microglia which represents the M1 polarization state in the mice brain under MPTP stimulation. No significant difference in the expression of p38/MAPK pathway was found in the nigrostriatal regions, while Nic could significantly inhibit the elevated p-JNK/JNK ratio and increase the declined p-ERK/ERK ratio in the substantia nigra of MPTP-exposed brains, which was further confirmed by the pretreatment of CYP2A5 inhibitor to decline the metabolic activity of Nic. Discussion: The molecular signaling mechanism by which Nic exerts its neuroprotective effects against PD may be achieved by regulating the JNK and ERK signaling pathways in the nigra-striatum related brain regions.

[1]  A. Björklund,et al.  A Combined α-Synuclein/Fibril (SynFib) Model of Parkinson-Like Synucleinopathy Targeting the Nigrostriatal Dopamine System , 2022, Journal of Parkinson's disease.

[2]  B. Picconi,et al.  Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson’s Disease , 2021, International journal of molecular sciences.

[3]  K. Kuča,et al.  Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[4]  M. Aschner,et al.  Novel Pharmacotherapies in Parkinson’s Disease , 2021, Neurotoxicity Research.

[5]  M. Xilouri,et al.  Neurons and Glia Interplay in α-Synucleinopathies , 2021, International journal of molecular sciences.

[6]  Kyeong-Man Kim,et al.  Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson’s Disease , 2021, International journal of molecular sciences.

[7]  A. Alhowail.  Molecular insights into the benefits of nicotine on memory and cognition , 2021, Molecular medicine reports.

[8]  Guanyu Zhu,et al.  Biomarkers and the Role of α-Synuclein in Parkinson’s Disease , 2021, Frontiers in Aging Neuroscience.

[9]  Jifeng Zhao,et al.  Activation of α7-nAChRs Promotes the Clearance of α-Synuclein and Protects Against Apoptotic Cell Death Induced by Exogenous α-Synuclein Fibrils , 2021, Frontiers in Cell and Developmental Biology.

[10]  Xiang Gao,et al.  Dietary nicotine intake and risk of Parkinson disease: a prospective study. , 2020, The American journal of clinical nutrition.

[11]  Liping Wang,et al.  Phosphorylation of Tau and α-Synuclein Induced Neurodegeneration in MPTP Mouse Model of Parkinson’s Disease , 2020, Neuropsychiatric disease and treatment.

[12]  M. Okun,et al.  Diagnosis and Treatment of Parkinson Disease: A Review. , 2020, JAMA.

[13]  Esperanza García,et al.  Chronic Systemic Inflammation Exacerbates Neurotoxicity in a Parkinson's Disease Model , 2020, Oxidative medicine and cellular longevity.

[14]  Yuting Hu,et al.  Maternal Nicotine Exposure During Gestation and Lactation Period Affects Behavior and Hippocampal Neurogenesis in Mouse Offspring , 2020, Frontiers in Pharmacology.

[15]  Fei Zou,et al.  p38 MAPK-DRP1 signaling is involved in mitochondrial dysfunction and cell death in mutant A53T α-synuclein model of Parkinson's disease. , 2019, Toxicology and applied pharmacology.

[16]  A. Schapira,et al.  Parkinson disease , 2019, European journal of neurology.

[17]  Xu Wang,et al.  Pharmacological Targeting of Microglial Activation: New Therapeutic Approach , 2019, Front. Cell. Neurosci..

[18]  Guangdong Zhang,et al.  Activation of α7‐nAChRs protects SH‐SY5Y cells from 1‐methyl‐4‐phenylpyridinium‐induced apoptotic cell death via ERK/p53 signaling pathway , 2019, Journal of cellular physiology.

[19]  S. Maji,et al.  α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis. , 2019, Biochimica et biophysica acta. Proteins and proteomics.

[20]  J. Trojanowski,et al.  α-Synuclein pathology in Parkinson’s disease and related α-synucleinopathies , 2019, Neuroscience Letters.

[21]  T. Nagao,et al.  The neonicotinoids acetamiprid and imidacloprid impair neurogenesis and alter the microglial profile in the hippocampal dentate gyrus of mouse neonates , 2019, Journal of applied toxicology : JAT.

[22]  M. Zarrindast,et al.  The modulatory role of nicotine on cognitive and non-cognitive functions , 2019, Brain Research.

[23]  B. Singh,et al.  The Role of PI3K/Akt and ERK in Neurodegenerative Disorders , 2019, Neurotoxicity Research.

[24]  M. Spillantini,et al.  Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology , 2019, International journal of molecular sciences.

[25]  Jia-wei Zhou,et al.  Neuroinflammation in the central nervous system: Symphony of glial cells , 2018, Glia.

[26]  C. Glorioso,et al.  Nicotine promotes neuron survival and partially protects from Parkinson’s disease by suppressing SIRT6 , 2018, Acta neuropathologica communications.

[27]  U. Maskos,et al.  Alpha6-Containing Nicotinic Acetylcholine Receptors Mediate Nicotine-Induced Structural Plasticity in Mouse and Human iPSC-Derived Dopaminergic Neurons , 2018, Front. Pharmacol..

[28]  Inhwa Hwang,et al.  MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration , 2018, Cell Death & Differentiation.

[29]  F. Shi,et al.  Depletion of microglia augments the dopaminergic neurotoxicity of MPTP , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  B. Hyman,et al.  Synaptic phosphorylated &agr;-synuclein in dementia with Lewy bodies , 2017, Brain : a journal of neurology.

[31]  I. Richard,et al.  Parkinson's disease psychosis: presentation, diagnosis and management. , 2017, Neurodegenerative disease management.

[32]  Lingli Zhou,et al.  Microglia Polarization with M1/M2 Phenotype Changes in rd1 Mouse Model of Retinal Degeneration , 2017, Front. Neuroanat..

[33]  N. Chen,et al.  Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease , 2017, Acta Pharmacologica Sinica.

[34]  I. Roy,et al.  Nicotine slows down oligomerisation of α-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson's disease. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[35]  Xiaoshuang Zhou,et al.  Nicotine suppresses the neurotoxicity by MPP+/MPTP through activating &agr;7nAChR/PI3K/Trx‐1 and suppressing ER stress , 2017, Neurotoxicology.

[36]  D. James Surmeier,et al.  Selective neuronal vulnerability in Parkinson disease , 2017, Nature Reviews Neuroscience.

[37]  T. Numakawa,et al.  Chronic glucocorticoid exposure suppressed the differentiation and survival of embryonic neural stem/progenitor cells: Possible involvement of ERK and PI3K/Akt signaling in the neuronal differentiation , 2016, Neuroscience Research.

[38]  S. Deweerdt.  Parkinson's disease: 4 big questions , 2016, Nature.

[39]  Zhiping P. Pang,et al.  Increased nicotine response in iPSC-derived human neurons carrying the CHRNA5 N398 allele , 2016, Scientific Reports.

[40]  Yingzhi Liu,et al.  Morphine Postconditioning Protects against Reperfusion Injury via Inhibiting JNK/p38 MAPK and Mitochondrial Permeability Transition Pores Signaling Pathways , 2016, Cellular Physiology and Biochemistry.

[41]  Paul J. Barrett,et al.  Post-translational modification of α-synuclein in Parkinson׳s disease , 2015, Brain Research.

[42]  T. Gould,et al.  Nicotine modulation of fear memories and anxiety: Implications for learning and anxiety disorders. , 2015, Biochemical pharmacology.

[43]  Suneil K. Kalia,et al.  Disease‐modifying strategies for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[44]  M. Zarrindast,et al.  The Modulatory Role of Dopamine in Anxiety-like Behavior. , 2015, Archives of Iranian medicine.

[45]  Jie Wu,et al.  Activation of α7 nicotinic acetylcholine receptors protects astrocytes against oxidative stress-induced apoptosis: Implications for Parkinson's disease , 2015, Neuropharmacology.

[46]  E. Choi,et al.  Compromised MAPK signaling in human diseases: an update , 2015, Archives of Toxicology.

[47]  R. Papke,et al.  The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions , 2015, Experimental Neurology.

[48]  G. Barreto,et al.  Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson’s disease , 2015, Front. Aging Neurosci..

[49]  M. Quik,et al.  Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders. , 2015, International review of neurobiology.

[50]  R. Tyndale,et al.  Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice , 2014, Neuropharmacology.

[51]  R. Tyndale,et al.  Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor. , 2014, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[52]  S. McCallum,et al.  Impact of Nicotine Metabolism on Nicotine’s Pharmacological Effects and Behavioral Responses: Insights from a Cyp2a(4/5)bgs-Null Mouse , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[53]  M. Lang,et al.  Function and regulation of the Cyp2a5/CYP2A6 genes in response to toxic insults in the liver. , 2012, Current drug metabolism.

[54]  Hitoshi Takahashi,et al.  The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders , 2013, Molecular Neurobiology.

[55]  M. Quik,et al.  Nicotine as a potential neuroprotective agent for Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[56]  R. Metherate,et al.  Nicotinic neuromodulation in auditory cortex requires MAPK activation in thalamocortical and intracortical circuits. , 2012, Journal of neurophysiology.

[57]  G. Kirby,et al.  CYP2A5 induction and hepatocellular stress: an adaptive response to perturbations of heme homeostasis. , 2011, Current drug metabolism.

[58]  Jinhe Li,et al.  α7 nAChR-mediated activation of MAP kinase pathways in PC12 cells , 2010, Brain Research.

[59]  Ming D. Li,et al.  Nicotinic Modulation of Innate Immune Pathways Via α7 Nicotinic Acetylcholine Receptor , 2010, Journal of Neuroimmune Pharmacology.

[60]  E. Choi,et al.  Pathological roles of MAPK signaling pathways in human diseases. , 2010, Biochimica et biophysica acta.

[61]  W. Humphreys,et al.  Role of CYP2A5 in the Clearance of Nicotine and Cotinine: Insights from Studies on a Cyp2a5-null Mouse Model , 2010, Journal of Pharmacology and Experimental Therapeutics.

[62]  M. Quik,et al.  Multiple roles for nicotine in Parkinson's disease. , 2009, Biochemical pharmacology.

[63]  C. C. Filgueiras,et al.  Anxiety-like behavior during nicotine withdrawal predict subsequent nicotine consumption in adolescent C57BL/6 mice , 2008, Behavioural Brain Research.

[64]  A. Rossini,et al.  Different modes of inhibition of mouse Cyp2a5 and rat CYP2A3 by the food-derived 8-methoxypsoralen. , 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[65]  T. Mauriala,et al.  Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[66]  Gwang Lee,et al.  Neuroprotective effect of nicotine on dopaminergic neurons by anti‐inflammatory action , 2007, The European journal of neuroscience.

[67]  R. Tyndale,et al.  Inhibition of Nicotine Metabolism by Methoxysalen: Pharmacokinetic and Pharmacological Studies in Mice , 2007, Journal of Pharmacology and Experimental Therapeutics.

[68]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[69]  R. Tyndale,et al.  Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5 , 2006, Psychopharmacology.

[70]  J. Schulz,et al.  Anti-apoptotic gene therapy in Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.

[71]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[72]  Tai-Hsien Wu,et al.  Effects of 5-methoxypsoralen (5-MOP) on arylamine N-acetyltransferase activity in the stomach and colon of rats and human stomach and colon tumor cell lines. , 2005, In vivo.

[73]  N. Jochnowitz,et al.  Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. , 2005, The journal of pain : official journal of the American Pain Society.

[74]  Antti Poso,et al.  Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. , 2005, Journal of medicinal chemistry.

[75]  M. Fennell,et al.  Targeting JNK3 for the treatment of neurodegenerative disorders. , 2004, Drug discovery today.

[76]  E. Hirsch,et al.  Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin , 2003, Brain Research.

[77]  E. Melamed,et al.  Apoptosis and Parkinson's disease , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[78]  S. Harper,et al.  MAPKs: new targets for neurodegeneration , 2003, Expert opinion on therapeutic targets.

[79]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[80]  W. Trager,et al.  Mechanism-based inactivation of P450 2A6 by furanocoumarins. , 1998, Biochemistry.